Health officials are warning that what many people dismiss as a routine summer stomach bug may actually be cyclosporiasis, as the U.S. experiences one of its largest foodborne parasite outbreaks on record.

The Centers for Disease Control and Prevention has confirmed more than 1,600 domestic cases of cyclosporiasis since May, with over 5,100 additional cases currently under investigation.

The intestinal infection is caused by Cyclospora (Cyclospora cayetanensis), a microscopic parasite that spreads through contaminated food or water.

IS LETTUCE STILL SAFE TO EAT AMID TACO BELL ILLNESS PROBE? DOCTORS ANSWER

The outbreak has sickened thousands of people, particularly in Midwestern states such as Michigan and Ohio, causing prolonged bouts of severe gastrointestinal illness.

Symptoms usually begin about one week after consuming contaminated food or water, although the incubation period can range from about two days to two weeks, according to the CDC.

Early symptoms can overlap with those of a common viral stomach bug, including abdominal pain, nausea and watery diarrhea. Some patients also experience loss of appetite, fatigue and weight loss.

The primary differences lie in how long the illness lasts and how severe the symptoms become, according to Dr. Kenneth Perry, an emergency physician based in South Carolina.

HIGHLY CONTAGIOUS STOMACH BUG SPREADS FAST, HITTING CERTAIN PATIENTS HARDEST

Routine stomach bugs are typically short-lived, resolving within 24 to 48 hours, the doctor said. Even if mild symptoms linger, patients generally feel better after two days.

“Cyclospora is different in this regard,” Perry told Fox News Digital. “It lasts longer, with far more profound watery, foul-smelling diarrhea and abdominal cramping.”

It is possible to test for Cyclospora, but healthcare providers must specifically request it, as the parasite is not routinely included in standard stool testing and many gastrointestinal PCR panels do not detect it, according to the CDC.

Diagnosis is made by examining stool specimens, although patients may need to submit several samples collected on different days, as even symptomatic people may not shed enough of the parasite for it to be readily detected, per the above source.

CLICK HERE TO SIGN UP FOR OUR HEALTH NEWSLETTER

If symptoms strongly suggest Cyclospora despite an initial negative test, the screening may need to be repeated, Perry noted.

A primary care physician is often the best point of contact for patients seeking a diagnosis, as most routine stool tests performed in emergency departments do not screen for Cyclospora. A family doctor can order the specialized test if it’s suspected.

CLICK HERE FOR MORE HEALTH STORIES

“The emergency department is the appropriate setting for treating downstream symptoms, such as nausea, diarrhea and dehydration,” Perry told Fox News Digital.

People who suspect they have contracted the parasite can also check FDA and CDC food safety alerts to see whether they may have been exposed to a recalled or implicated product.

Patients should also focus on staying hydrated by monitoring their urine output. Perry recommends using over-the-counter pediatric formulas, which offer a more effective salt-to-sugar ratio than commercial sports drinks.

CLICK HERE TO DOWNLOAD THE FOX NEWS APP

Anyone whose diarrhea lasts more than two to three days, worsens or is accompanied by signs of dehydration should contact a primary care physician.

TEST YOURSELF WITH OUR LATEST LIFESTYLE QUIZ

Unlike most viral stomach bugs, Cyclospora is treatable with prescription antibiotics. The CDC recommends trimethoprim-sulfamethoxazole (TMP-SMX) as the standard treatment, while people who cannot take sulfa drugs should discuss alternatives with their healthcare provider.

Neurologists are warning that popular weight-loss medications could have severe negative effects on neurodegenerative conditions like ALS.

Jinsy Andrews, MD, a neurologist and director of NYU Langone’s ALS Center, says the very mechanism that makes these drugs popular — rapid weight loss — can go against the biological needs of patients with neuromuscular disorders.

GLP-1 agonists have shown to be highly effective at managing diabetes and obesity, which are major health concerns across the population. However, the doctor emphasized that the clinical rules shift when dealing with amyotrophic lateral sclerosis (ALS).

DR OZ LINKS OBESITY TO CHRONIC DISEASE SURGE, SAYS GLP-1S CAN ‘JUMPSTART’ BETTER HEALTH

In addition to mitigating some of the inflammation related to obesity and diabetes, GLP-1 medications have been linked to other protective effects.

The therapies have been helpful in reducing cardiovascular disease, stroke risk, liver disease and addiction, according to Andrews.

However, when it comes to an incurable neurodegenerative disease, losing weight and body fat can accelerate a patient’s physical decline.

For an ALS patient, losing weight can cause the condition to progress faster, Andrews said, because the disease’s unique traits make it dangerous to be in a caloric deficit.

BIG MEDICARE CHANGE SLASHES WEIGHT-LOSS DRUG COSTS FOR ELIGIBLE SENIORS

In fact, standard clinical care guidelines for ALS often recommend that patients actively maintain or even gain weight to help preserve their remaining nerve and muscle function.

“In certain conditions where hypermetabolism is something that negatively affects the disease […] losing weight actually makes the disease worse and move faster,” Andrews told Fox News Digital..

CLICK HERE FOR MORE HEALTH STORIES

“So, in the setting of a person with ALS — whether they have diabetes or not — using GLP-1s may actually worsen the disease and make for a rapid progression.”

In a 2025 case report published in the medical journal Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, a 52-year-old ALS patient was prescribed semaglutide to treat her type 2 diabetes.

CLICK HERE TO SIGN UP FOR OUR HEALTH NEWSLETTER

Prior to starting the medication, her physical functions were declining at a predictable rate on the standard ALS rating scale.

According to the case report, the patient lost 25 pounds in three months. At the same time, she experienced a sudden, dramatic shift in her disease trajectory, with symptoms worsening significantly.

“GLP-1s may actually worsen the disease and make for a rapid progression.”

Once the semaglutide was discontinued at the advice of medical professionals, the patient’s rapid physical decline stabilized.

CLICK HERE TO DOWNLOAD THE FOX NEWS APP

Andrews pointed out that this published documentation, alongside retrospective cohort data of ALS patients with diabetes, provides growing evidence that clinicians must be careful and thoughtful about who they treat with GLP-1 receptor agonists.

While weight-loss medications offer significant benefits for many patients, experts say maintaining body weight and muscle mass remains an important consideration for people with neurodegenerative diseases.

“Patient safety is of utmost importance to Novo Nordisk, and we take all reports about adverse events from the use of our medicines very seriously,” Ambre James-Brown, global head and AVP of global media at Novo Nordisk, maker of Ozempic and Wegovy, told Fox News Digital.

TEST YOURSELF WITH OUR LATEST LIFESTYLE QUIZ

“It’s important to note that ALS and other neurodegenerative diseases are not listed adverse reactions or warnings and precautions in the prescribing information for our semaglutide products, including Ozempic or Wegovy,” he added.

Millions of Americans with high cholesterol now have a new treatment option, as the FDA has approved the first once-daily oral PCSK9 inhibitor.

Merck, the New Jersey-based manufacturer of Lipfendra (enlicitide), announced the approval on Thursday.

Lipfendra blocks the action of PCSK9, a naturally occurring protein that affects how the liver removes LDL (“bad”) cholesterol from the bloodstream.

DR OZ LINKS OBESITY TO CHRONIC DISEASE SURGE, SAYS GLP-1S CAN ‘JUMPSTART’ BETTER HEALTH

“PCSK-9 is a protein that works in the liver, preventing the recycling of LDL receptors, as a result increasing bad cholesterol in the blood,” Dr. Marc Siegel, Fox News senior medical analyst, told Fox News Digital.

“In the caveman days, this was useful when we were hunter-gatherers and didn’t always have food, but now it mainly forms plaques that lead directly to heart disease.”

YOUR RESTING HEART RATE COULD REVEAL MORE ABOUT YOUR HEALTH THAN YOU THINK, DOCTORS SAY

The pill is approved as an add-on to diet and other LDL-lowering therapies in adults with high cholesterol, including inherited forms of high cholesterol, Merck stated.

In phase 3 clinical trials, Lipfendra was shown to reduce LDL cholesterol by roughly 56% to 60% when combined with statin therapy.

TEST YOURSELF WITH OUR LATEST LIFESTYLE QUIZ

“This is around double the impact of statins,” Siegel noted.

The pill was generally well-tolerated in the trials, Merck reported. The most common side effects were diarrhea and dizziness, while serious side effects and treatment discontinuations occurred at rates similar to those in the placebo group.

Statins, which work by blocking an enzyme in the liver that the body uses to make cholesterol, are the most commonly prescribed cholesterol-lowering medications, according to the American Heart Association.

CLICK HERE TO SIGN UP FOR OUR HEALTH NEWSLETTER

For many people, statins are effective on their own. But for some patients who have very high cholesterol levels, inherited forms of high cholesterol or adverse side effects when taking statins, another medication — such as a PCSK9 inhibitor like Lipfendra — may be necessary, per the AHA.

Until now, PCSK9 inhibitors — such as Repatha and Praluent — have only been available as injections, a factor experts say may have contributed to their underuse.

CLICK HERE FOR MORE HEALTH STORIES

“Repatha, the injectable form, is very useful, with few side effects,” Siegel noted. “The oral form, Lipfendra, is also well-tolerated and just as effective.”

Additional research is needed to determine whether Lipfendra also reduces the risk of heart attacks, strokes and cardiovascular deaths. Results from a large clinical trial are expected to be available in 2029, Merck stated.

CLICK HERE TO DOWNLOAD THE FOX NEWS APP

“Steve Nissen, longtime head of preventive cardiology at Cleveland Clinic, tells me that the lower the better when it comes to LDL cholesterol, especially in those at risk for heart disease,” Siegel added.